PARP1 and neoplasm: Consistent with lower tumor PARP-1 levels, and consistent with lower in vitro uptake of 18F-olaparib, intravenous administration resulted in lower average uptake of 18F-olaparib in these tumors (2.59 ± 0.32 %ID/g), although this was not statistically significant.